Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 5, 2026Cancer Research

OriC613: A Dual-Targeting CAR-T Approach for Gastric and Pancreatic Cancers

View Full Paper
Ask AI
Bookmark
Share

Authors

XHX. HeSYShasha YangHGHao Guo

Discussion

Loading...

Member takes

Overview

Preclinical findings show that OriC613 enhances tumor selectivity in gastric and pancreatic cancers, suggesting a promising therapeutic strategy.

Key Points

  • This research aims to develop a dual-targeting CAR-T cell therapy to enhance treatment efficacy for gastric and pancreatic cancers.
  • Developed OriC613, a dual-targeting CAR-T cell based on AND-logic gate.
  • Engineered high-affinity anti-CLDN18.2 scFv combined with moderate-affinity anti-MSLN VHH.
  • Evaluated safety and efficacy in preclinical gastric and pancreatic cancer models.
  • OriC613 showed no cytotoxic activity against normal gastric models.
  • Demonstrated enhanced potency against dual-positive tumors compared to conventional CAR-T cells.
  • Significant tumor regression observed in high-burden gastric models with sustained T-cell persistence.

Cite This Study

He et al. (2026) studied this question.

synapsesocial.com/papers/69d1fd62a79560c99a0a36c9https://doi.org/10.1158/1538-7445.am2026-1534
View Full Paper
Ask AI
Bookmark
Share